Read More Pharma Industry News Why oncology investors are watching Cogent Biosciences, Inc.’s PEAK data closely Why investors are closely watching Cogent Biosciences’ PEAK data and what bezuclastinib could mean for valuation, revenue growth, and oncology market sentiment. bySoujanya RaviApril 3, 2026